Tumor Microenvironment Equipment & Supplies
70 equipment items found
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment ...
Manufactured by:SynVivo, Inc. based inHuntsville, ALABAMA (USA)
SynTumor is a 3D tissue model for real-time visualization and quantitative assessment of cell-cell and cell-drug interactions in a physiologically and morphologically realistic tumor microenvironment. The system enables (a) circulation in the microvasculature, (b) transport across the vessel walls, and (c) delivery to the tumors. Starting with ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes and TME (tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor ...
Manufactured by:Sigma-Aldrich based inBellefonte, PENNSYLVANIA (USA)
SynTumor is a 3D tissue model for real-time visualization and quantitative assessment of cell-cell and cell-drug interactions in a physiologically and morphologically realistic tumor ...
Manufactured by:Akoya Biosciences based inMarlborough, MASSACHUSETTS (USA)
Unraveling the complex and dynamic tumor microenvironment requires the assessment of spatial relationships between tumor and immune cells. Multiplex imaging utilizing tumor and immunologic markers can reveal the spatial relationships between tumor and immune cells, leading to the discovery of spatial ...
by:Celluris based inSão Paulo, BRAZIL
RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and another domain that binds to an extracellular molecule from tumoral microenvironment. ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several ...
by:Ionpath, Inc. based inMenlo Park, CALIFORNIA (USA)
L-arginine is a necessary metabolite for T cell receptor signaling and T cell proliferation. Arginase is induced by inflammation. In cancer, MDSCs within the tumor microenvironment (TME) produce arginase-1 resulting in low levels of available L-arginine within the TME leading to attenuated T cell ...
Manufactured by:NanoString based inSeattle, WASHINGTON (USA)
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated ...
by:Traws Pharma based inNewtown, PENNSYLVANIA (USA)
In addition, rigosertib may be a potent immunomodulator via the stimulation of neoantigen expression resulting in attraction of immune cells into the tumor microenvironment and thus making the tumor more susceptible to ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic drugs. Therefore, ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to unleash the power of the immune system, including genetically engineered cell ...